

- glaucoma. *British Journal of Ophthalmology* 73 (12): 975-979, 1989
- Waitzman MB, King CD. Prostaglandin influences on intraocular pressure and pupil size. *American Journal of Physiology* 212: 329-334, 1967
- Weinreb RN, Kass MA, Lippa EA, et al. MS-507 vs MK-417: comparative efficacy of two topically active carbonic anhydrase inhibitors. *Ophthalmology* 97 (Suppl. 1): 124, 1990
- Weinreb RN, Ruderman J, Juster R, et al. Immediate intraocular pressure response to argon laser trabeculoplasty. *American Journal of Ophthalmology* 95: 279-286, 1983
- West DR, Lischwe TD, Thompson VM, et al. Comparative efficacy of the beta-blockers for the prevention of increased intraocular pressure after cataract extraction. *American Journal of Ophthalmology* 106: 168-173, 1988

- Zimmerman TJ. Acetazolamide and methazolamide. *Annals of Ophthalmology* 10: 509-510, 1978
- Zimmerman TJ. Pilocarpine. *Ophthalmology* 88: 85-88, 1981
- Zimmerman TJ. Mechanism of action of topical epinephrine. Editorial. *Annals of Ophthalmology* 16: 307-308, 1984
- Zimmerman TJ, Baumann JD, Hetherington J. Side effects of timolol. *Survey of Ophthalmology* 2: 243-249, 1983
- Zimran A, Beutler E. Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? Editorial. *American Journal of Ophthalmology* 104: 654-658, 1987

Correspondence and reprints: Dr Lawrence M. Hurvitz, 3920 Bee Ridge Road, Building F, Suite B, Sarasota, FL 34233, USA.

Errata

Vol. 40, No. 6, 1990, page 871: In section 3, line 21, the phrase '... preferential affinity for striatal dopaminergic systems...' should read '... preferential affinity for *extrastriatal* dopaminergic systems...'; **page 876:** due to an omission in the original publication, the incidence of tremor associated with haloperidol (28%) was unfortunately not included in fig. 4.




Fig. 4. Incidence of adverse events in patients from 9 controlled studies treated with remoxipride (n = 667) [□] or haloperidol (n = 437) [□]. Blurred vision and hypo/akinesia were each reported by fewer than 10% of remoxipride recipients (adapted from Lewander et al. 1990).

Vol. 41, No. 2, 1991: the table on page 195 (large box on left) and text in left-hand column on page 196 (line 23) should read *propoxyphene HCl*.

Vol. 40 (Suppl. 2), 1990, page 71: The 'Closing Remarks' attributed to Professor T. Omae in this supplement were not presented at the symposium as inferred. Professor Omae, whose intended role was as co-chairman of Session I, was in fact absent from most of the meeting because of an unforeseen disruption of his travel plans. The text incorrectly titled 'Closing Remarks' was prepared from notes received from Professor Omae which we wrongly assumed were intended for publication in the *Drugs* supplement. Furthermore, because of a grammatical misunderstanding, Professor Omae's intended meaning was misinterpreted: isradipine is *not yet available* in Japan for the treatment of hypertension. We apologise for any confusion this may have caused.